Immune Response to Bivalent or Quadrivalent Human Papilloma Virus vaccination in Patients with Chronic Renal Failure Immunrespons efter vaccination mod humant papilloma virus med bivalent eller tetravalent HPV vaccine hos personer med kronisk nyresygdom
Latest Information Update: 02 Jul 2013
At a glance
- Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary) ; Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Anal cancer; Cervical cancer; Cervical dysplasia; Human papillomavirus infections; Penile cancer
- Focus Therapeutic Use
- Acronyms IPAR
- 01 May 2013 Status changed from recruiting to discontinued as reported by European Clinical Trials Database record.
- 04 Aug 2012 New trial record